Targeting Oxidative Stress in Chronic Beryllium Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Beryllium Disease

In brief

The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive effects of prednisone, and thus reduce the immune response to beryllium.

Key facts

Study ID
NCT01088243
Run by
National Jewish Health
People needed
18
Starts
2010-03-01
Expected to finish
2015-03-01
Last updated by the study team
2018-10-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.